Patient Registry Analyses: Seize the Data, but Caveat Lector

Journal of Pediatrics

Volumn 153, Issue 6, 2008, Pages 733-735

  Schechter, Michael S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; DORNASE ALFA; TOBRAMYCIN;

CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE ASSOCIATION; EDITORIAL; HEALTH CARE QUALITY; HUMAN; LUNG FUNCTION; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; QUALITY OF LIFE; REGISTER; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT;

CHILD; CYSTIC FIBROSIS; HUMANS; MEDICAL RECORDS; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; TREATMENT OUTCOME;

EID: 56249132492     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.09.011     Document Type: Editorial

References (17)

1. Michel G., von der Weid N.X., Zwahlen M., Adam M., Rebholz C.E., and Kuehni C.E. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly 137 (2007) 502-509
2. Steele J.R., Wellemeyer A.S., Hansen M.J., Reaman G.H., and Ross J.A. Childhood Cancer Research Network: a North American Pediatric Cancer Registry. Cancer Epidemiol Biomarkers Prev 15 (2006) 1241-1242
3. Walsh M.C., Yao Q., Horbar J.D., Carpenter J.H., Lee S.K., and Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 118 (2006) e1328-e1335
4. Eng C.M., Fletcher J., Wilcox W.R., Waldek S., Scott C.R., Sillence D.O., et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30 (2007) 184-192
5. Dowling N.F., Beckman M.G., Manco-Johnson M., Hassell K., Philipp C.S., Michaels L.A., et al. The US Thrombosis and Hemostasis Centers pilot sites program. J Thromb Thrombolysis 23 (2007) 1-7
6. Pitukcheewanont P., Desrosiers P., Steelman J., Rapaport R., Fuqua J.S., Kreher N.C., et al. Issues and trends in pediatric growth hormone therapy: an update from the GHMonitor observational registry. Pediatr Endocrinol Rev 5 Suppl 2 (2008) 702-707
7. In: Gliklich R., and Dreyer N. (Eds). Registries for evaluating patient outcomes: a user's guide (2007), Agency for Healthcare Research and Quality, Rockville, MD. http://effectivehealthcare.ahrq.gov/repFiles/PatOutcomes.pdf AHRQ publication 07-EHC001-1
8. Curtis J.R., Burke W., Kassner A., and Aitkin M.L. Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am J Respir Crit Care Med 155 (1997) 1921-1924
9. Schechter M.S., and Margolis P.A. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatrics 132 (1998) 260-264
10. McPhail G., Acton J.D., Fenchel M.C., Amin R.S., and Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 153 (2008) 752-757
11. Schechter M.S., and Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 147 (2005) 295-301
12. Morgan W.J., Butler S.M., Johnson C.A., Colin A.A., FitzSimmons S.C., Geller D.E., et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada. Pediatr Pulmonol 28 (1999) 231-241
13. Quittner A.L., Buu A., Messer M.A., Modi A.C., and Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128 (2005) 2347-2354
14. Schmoor C., Caputo A., and Schumacher M. Evidence from nonrandomized studies: a case study on the estimation of causal effects. Am J Epidemiol 167 (2008) 1120-1129
15. Ren C., Pasta D., Rasouliyan L., Wagener J., Konstan M., and Morgan W. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 153 (2008) 746-751
16. Balfour-Lynn I.M., Lees B., Hall P., Phillips G., Khan M., Flather M., et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173 (2006) 1356-1362
17. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 151 (2007) 134-139